The most notable gene alterations discovered in patients with SCLC are almost ubiquitous loss of tumor suppressors p53 and retinoblastoma susceptibility gene (RB1), as well as MYC amplification (Semenova, Nagel, & Berns, 2015). This evidence concerns the gene TP53 and small cell lung carcinoma.